Adrenocortical Carcinoma - Featured Clinical Trials
The following list shows Featured Clinical Trials for a specific type of cancer. You may also want to view:
- Targeted Antibody Therapy for Metastatic Adrenocortical Carcinoma
(Posted: 11/02/2010) - In this clinical trial, 20 patients with recurrent, metastatic, or otherwise unresectable adrenocortical carcinoma who have not been previously treated with systemic therapies will receive IMC-A12 and mitotane to determine the safety of the combined therapy. If the combination is safe, an additional 102 patients will be randomly assigned to receive the combined treatment or mitotane alone.
- Targeted Combination Therapy for Advanced Solid Tumors
(Posted: 07/19/2005) - In this study, researchers are assessing the safety and combined effectiveness of bevacizumab and a second drug called sorafenib. Both bevacizumab and sorafenib inhibit the formation of blood vessels to tumors and may act synergistically when combined.
- Combination Chemotherapy for Adrenocortical Cancer
(Posted: 01/18/2005) - This trial combines a drug called tariquidar with chemotherapy to treat adrenocortical carcinoma. Tariquidar may make cancer cells more sensitive to chemotherapy.